Repligen (RGN) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGN Analyst Ratings

Moderate Buy

9 Buy

5 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGN Stock 12 Month Forecast

Average Price Target

CHF148.42

Based on 14 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is CHF148.42 with a high forecast of CHF169.40 and a low forecast of CHF122.75. The average price target represents a ― change from the last price of ―.

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

Highest Price TargetCHF169.40

Average Price TargetCHF148.42

Lowest Price TargetCHF122.75

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

CHF147.55

Buy

―

Reiterated

05/05/25

Repligen's Strategic Growth and Resilience Drive Buy Rating with $180 Price Target

Robert WassermanBenchmark Co.

Benchmark Co.

―

Hold

―

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Matt HewittCraig-Hallum

Craig-Hallum

CHF167.22

Buy

―

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: Delcath Systems (NASDAQ: DCTH), Repligen (NASDAQ: RGEN) and CareDx (NASDAQ: CDNA)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

CHF169.68

Buy

―

Reiterated

04/30/25

Stifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)

Puneet SoudaLeerink Partners

Leerink Partners

CHF147.55→CHF163.94

Buy

―

Reiterated

04/30/25

Repligen's Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure

Conor McNamaraRBC Capital

RBC Capital

CHF165.58→CHF154.93

Buy

―

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Repligen (NASDAQ: RGEN) and Zynex (NASDAQ: ZYXI)

Doug SchenkelWolfe Research

Wolfe Research

CHF131.15

Buy

―

Upgraded

04/29/25

Repligen upgraded to Outperform from Peer Perform at Wolfe ResearchRepligen upgraded to Outperform from Peer Perform at Wolfe Research

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

CHF163.94→CHF155.74

Buy

―

Reiterated

04/29/25

Repligen price target lowered to $190 from $200 at JPMorganRepligen price target lowered to $190 from $200 at JPMorgan

Matthew Stanton, CFAJefferies

Jefferies

CHF135.25→CHF131.15

Hold

―

Reiterated

04/29/25

Repligen (RGEN) PT Lowered to $914 at JefferiesJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.

Matt LarewWilliam Blair

William Blair

―

Buy

―

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Acquisition Justify Buy Rating

Brendan SmithTD Cowen

TD Cowen

CHF163.94

Buy

―

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Positioning Earns 'Buy' Rating from Analyst

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

CHF122.96

Hold

―

Reiterated

04/29/25

Repligen's Fair Valuation and Cautious Growth Outlook Lead to Hold Rating

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Reiterated

04/08/25

Repligen (RGEN) Gets a Hold from Guggenheim

Daniel Markowitz CFAEvercore ISI

Evercore ISI

CHF127.06

Hold

―

Initiated

03/18/25

Repligen initiated with an In Line at Evercore ISIRepligen initiated with an In Line at Evercore ISI

Brandon CouillardWells Fargo

Wells Fargo

CHF147.55

Buy

―

Reiterated

03/03/25

Analysts Offer Insights on Healthcare Companies: Zai Lab (NASDAQ: ZLAB) and Repligen (NASDAQ: RGEN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

CHF147.55

Buy

―

Reiterated

05/05/25

Repligen's Strategic Growth and Resilience Drive Buy Rating with $180 Price Target

Robert WassermanBenchmark Co.

Benchmark Co.

―

Hold

―

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Matt HewittCraig-Hallum

Craig-Hallum

CHF167.22

Buy

―

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: Delcath Systems (NASDAQ: DCTH), Repligen (NASDAQ: RGEN) and CareDx (NASDAQ: CDNA)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

CHF169.68

Buy

―

Reiterated

04/30/25

Stifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)

Puneet SoudaLeerink Partners

Leerink Partners

CHF147.55→CHF163.94

Buy

―

Reiterated

04/30/25

Repligen's Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure

Conor McNamaraRBC Capital

RBC Capital

CHF165.58→CHF154.93

Buy

―

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Repligen (NASDAQ: RGEN) and Zynex (NASDAQ: ZYXI)

Doug SchenkelWolfe Research

Wolfe Research

CHF131.15

Buy

―

Upgraded

04/29/25

Repligen upgraded to Outperform from Peer Perform at Wolfe ResearchRepligen upgraded to Outperform from Peer Perform at Wolfe Research

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

CHF163.94→CHF155.74

Buy

―

Reiterated

04/29/25

Repligen price target lowered to $190 from $200 at JPMorganRepligen price target lowered to $190 from $200 at JPMorgan

Matthew Stanton, CFAJefferies

Jefferies

CHF135.25→CHF131.15

Hold

―

Reiterated

04/29/25

Repligen (RGEN) PT Lowered to $914 at JefferiesJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.

Matt LarewWilliam Blair

William Blair

―

Buy

―

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Acquisition Justify Buy Rating

Brendan SmithTD Cowen

TD Cowen

CHF163.94

Buy

―

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Positioning Earns 'Buy' Rating from Analyst

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

CHF122.96

Hold

―

Reiterated

04/29/25

Repligen's Fair Valuation and Cautious Growth Outlook Lead to Hold Rating

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Reiterated

04/08/25

Repligen (RGEN) Gets a Hold from Guggenheim

Daniel Markowitz CFAEvercore ISI

Evercore ISI

CHF127.06

Hold

―

Initiated

03/18/25

Repligen initiated with an In Line at Evercore ISIRepligen initiated with an In Line at Evercore ISI

Brandon CouillardWells Fargo

Wells Fargo

CHF147.55

Buy

―

Reiterated

03/03/25

Analysts Offer Insights on Healthcare Companies: Zai Lab (NASDAQ: ZLAB) and Repligen (NASDAQ: RGEN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

1 Month

xxx

Success Rate

10/17 ratings generated profit

Average Return

+2.87%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +2.87% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+0.24%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +0.24% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

10/22 ratings generated profit

Average Return

+16.63%

reiterated a buy rating last month

Copying Daniel Arias's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +16.63% per trade.

2 Years

xxx

Success Rate

7/22 ratings generated profit

Average Return

+19.25%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 31.82% of your transactions generating a profit, with an average return of +19.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGN Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGN has received 20 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. RGN average Analyst price target in the past 3 months is 148.42.

Each month's total comprises the sum of three months' worth of ratings.

RGN Financial Forecast

RGN Earnings Forecast

Next quarter’s earnings estimate for RGN is CHF0.32 with a range of CHF0.30 to CHF0.38. The previous quarter’s EPS was CHF0.32. RGN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.96% of the time in the same period. In the last calendar year RGN has Outperformed its overall industry.

RGN Sales Forecast

Next quarter’s sales forecast for RGN is CHF143.34M with a range of CHF138.37M to CHF146.81M. The previous quarter’s sales results were CHF138.67M. RGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.25% of the time in the same period. In the last calendar year RGN has Outperformed its overall industry.

RGN Stock Forecast FAQ

What is CH:RGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen Corp’s 12-month average price target is 148.42.

What is CH:RGN’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:RGN, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Repligen Corp a Buy, Sell or Hold?

Repligen Corp has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.

What is Repligen Corp’s share price target?

The average share price target for Repligen Corp is 148.42. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF169.40 ,and the lowest forecast is CHF122.75. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Repligen Corp?

Repligen Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Repligen Corp?

To buy shares of CH:RGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Repligen (RGN) Stock Forecast & Price Target

RGN Analyst Ratings

RGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGN Analyst Recommendation Trends

RGN Financial Forecast

RGN Earnings Forecast

RGN Sales Forecast

RGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts